| Management Team |
 |
 |
|
Mr. Jeremy Curnock Cook BA(Hons), MA
At Rothschild, Mr. Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market and the launch of a joint venture with Johnson & Johnson Development Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage investments in Europe, as well as the conception and launch of the International Biotechnology Trust (IBT). IBT was launched in 1994 as a publicly listed investment trust focussed internationally on mid stage investments in Life Sciences. Prior to joining Rothschild, Mr Curnock Cook founded the International Biochemicals Group (IBG) in 1975, and built an 80-person company focused on the development and commercialisation of products containing tailored microbial strains for application in industrial pollution control and agriculture. IBG’s clients included multinationals McDonalds and Royal Dutch Shell. Following the successful sale of IBG to Royal Dutch Shell in 1985, Mr Curnock Cook managed the integration process into Shell operations prior to being invited to join Rothschild in 1987. Mr. Curnock Cook has served on more than 30 boards of directors in the healthcare and medical sciences sector in the UK, Europe, USA, Canada, Japan and Australia. Current board positions include:
Previous board positions include:
He is also a past board member of Rothschild Asset Management. Mr Curnock Cook received his MA in Natural Sciences from Trinity College in Dublin in 1971, and was a research scientist at the Institute of Cancer Research from 1972 to 1973.
Dr. Nicholas Draeger PhD, MBA
Dr. Stewart Washer BSc (Hons), PhD
Stewart has more than 20 years experience in the sector. Stewarts experience in the life science sector includes, rasing seed capital and completing the successful IPO for Phylogic Ltd on the Australian Stock Exchange, as the founding CEO. Managing the commercialisation of intellectual property from AgResearch in New Zealand with 650 scientists and A$130m revenues as the CEO of Celentis. Stewart foundered a number of successful technology companies, generating over A$30 milion in product revenue, and completed a number of successful trade sales. In addition, he has been a managing executive and techical team leader in the agrifood, industrial and environmental sectors. In the investment sector, he is assisting BioPacific Ventures, a NZ$120 life science fund. Stewart is currently CEO of Calzada Ltd (ASX:CZD), a Director of Genesis R&D Ltd (ASX:GEN), Healthlinx Ltd (ASX:HTX) and AusBiotech Ltd; as well as a Senator of Murdoch University and a Venture Partner with the €1.5 billion Swiss Inventages Fund.
Dr. Nora Frey PhD
Mr. Jonathan Buckley B.Ec, ASIA
He joined Intersuisse in Melbourne in 1997 after spending seven years in London, with KPMG Strategy Consulting, Barclays de Zoete Wedd and Rothschild Asset Management. After joining KPMG in 1987 after graduating with a Bachelor of Economics degree, Jonathan developed expertise in business planning, corporate acquisitions and divestitures, valuations, financial modelling, capital structures, due diligence and corporate actions for publicly listed companies. He is a Fellow of the Financial Services Institute of Australia. Jonathan has overseen the corporate resource and biotech sector activity for corporate advisory projects to a significant number of resources, energy and life science companies, including: strategy consulting, information memorandum preparation, project feasibility plans, M&A, IPO and secondary fund raisings, with growing emphasis on the introduction of Asian partners/investors to Australian companies.
Michael Laletas LLB (Hon), BEng (Mech), Grad.Dip.Bank.Fin.
As Head of Institutional Investors Group with the Commonwealth Bank he was involved in advising institutional investors, fund managers and corporates with regards to structured financial projects and securities in Australia and Asia. His corporate advisory activities have contributed to the development of expertise specifically in structured finance but also in valuations, financial modelling and mergers and acquisition in mid cap companies.
|
| Last Updated on Monday, 31 January 2011 22:17 |
Jeremy Curnock Cook, the former head of the life science private equity team at Rothschild Asset Management and an active investor in the Australian life science sector.
Nicholas has upwards of 18 years of experience in the healthcare and finance industries. Nicholas has extensive experience in strategy, global business development and licensing, and healthcare finance. Nicholas started his career at Roche in the field of Alzheimer’s research and later was part of the Global Business Development team, specialising in M&A and licensing. At Recordati, he was Director of International Business Development. Later, Nicholas headed the Biotech sell-side research group at the French finance group, Credit Agricole Indosuez Cheuvreux, and was scientific advisor for the healthcare research team. Nicholas also has extensive experience in research, analysis, financial modelling and investing in healthcare companies, first as a member of the management team of BB Biotech and later at Adamant Biomedical Investments both in Switzerland, where he specialised in investments in Asia, Australia and South Africa, as well as venture capital on a global basis. Nicholas was a Senior Research Scientists in health economics at the University Hospital Basel, Switzerland. Nicholas is also a Founder and Managing Director of Cederberg Advisors GmbH in Switzerland; and Founder and Director of Algae Biotechnology Products Limited in the UK. Nicholas is currently an advisor to the government-sponsored Innovation Fund in South Africa. Nicholas holds a Bsc (Hons) in Chemical Engineering from the University of Natal, Durban, South Africa, a PhD from the University of Cambridge, UK, in Biochemical Engineering, and a MBA from the University of Warwick, UK.
Nora brings more than 15 years of professional experience in the healthcare research and investment field. She studied modern biology (microbiology, biochemistry) and economics in Basel and holds a masters degree in Microbiology and a PhD in Biochemistry in the field of drug-induced autoimmune diseases from the University of Basel. She was partner at Bellevue Group, Zug, Switzerland and part of the BB Biotech management team managing up to CHF 4 bn in public and private biotech investments. In 2000 she conceived of, and founded Adamant Biomedical Investments AG in Basel, Switzerland, a successful healthcare asset management boutique, which manages different healthcare funds. As CIO, Nora headed research and portfolio management, and led the innovation and expansion of the range of funds under management. During this time, the funds under management grew from CHF 50 mn to approx. CHF 1 bn. In addition, to research and fund management experience, Nora’s roles included advising numerous companies, and collaboration with SWX and ZKB’s Corporate Finance group regarding listings of foreign companies in Switzerland.
Director of the Fund Manager and Deputy Chairman of Intersuisse Holdings Ltd, based in Melbourne. Following a strategy consulting role with KPMG he joined Rothschild Asset Management in London in the late 1990s as a senior manager. He has advised over thirty Australian life science companies and has been responsible for the development of Intersuisse Asia Pacific fund management across medical sciences, resources, and private equity.
Michael Laletas has almost 20 years investment banking experience specialising in areas of alternative funding, corporate advisory and property portfolio management. Michael began his career as a Fund Manager/Analyst with capital markets roles for Rothschild and the Commonwealth Bank of Australia.